Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2006-09-19
2006-09-19
Housel, James (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
C424S185100, C424S093100, C424S093200, C424S093300, C424S202100, C424S205100, C435S069100, C435S235100
Reexamination Certificate
active
07108855
ABSTRACT:
The present invention relates to a method for purifying recombinant HCV single or specific oligomeric envelope proteins selected from the group consisting of E1 and/or E2 and/or E1/E2, characterized in that upon lysing the transformed host cells to isolate the recombinantly expressed protein a disulphide bond cleavage or reduction step is carried out with a disulphide bond cleavage agent. The present invention also relates to a composition isolated by such a method. The present invention also relates to the diagnostic and therapeutic application of these compositions. Furthermore, the invention relates to the use of HCV E1 protein and peptides for prognosing and monitoring the clinical effectiveness and/or clinical outcome of HCV treatment
REFERENCES:
patent: 4395395 (1983-07-01), Tabor et al.
patent: 5308750 (1994-05-01), Mehta et al.
patent: 5514539 (1996-05-01), Bukh et al.
patent: 5610009 (1997-03-01), Watanabie et al.
patent: 5670152 (1997-09-01), Weiner et al.
patent: 5830691 (1998-11-01), Miyamura et al.
patent: 5871962 (1999-02-01), Bukh et al.
patent: 5919454 (1999-07-01), Brechot
patent: 5942234 (1999-08-01), Ralston et al.
patent: 6150134 (2000-11-01), Maertens et al.
patent: 6245503 (2001-06-01), Maertens et al.
patent: 6613333 (2003-09-01), Leroux-Roels et al.
patent: WO 92/08734 (1992-05-01), None
patent: WO 93/02103 (1993-02-01), None
patent: WO 93/04205 (1993-03-01), None
patent: WO 93/15193 (1993-08-01), None
patent: WO95/12677 (1995-05-01), None
patent: WO 96 04385 (1996-02-01), None
patent: WO 98 21338 (1998-05-01), None
patent: WO99/67285 (1999-12-01), None
patent: WO03/051912 (2003-06-01), None
Liang et al. Annual of internal Medicine 2000, vol. 132, No. 4, pp. 296-305.
Ghany et al. Hepatology 2003, vol. 38, pp. 1289-1296.
Ghany et al. HEPATOLOGY, 2003, vol. 38, No. 5, pp. 109-1094.
Lechner et al. The Royl Society 2000, vol. 355, pp. 1085-1092.
Bukh et al. Intervirology 2001, vol. 44, pp. 132-142.
Fournillier et al. J. Virol. 2001, vol. 75 No. 24, pp. 12088-120977.
Choo et al, “Vaccination of Chimpanzees Against . . . Hepatitis C Virus”, Proc. Natl. Acad. Sci., 1994, pp. 1294-1298.
Lanford et al, “Analysis of Hepatitis C Virus . . . ”, Virology 197, pp. 225-235, 1993.
Nishihara et al, “Secretion and Purificatin of Hepatitis C . . . ”, Gene 129; 207-214, 1993.
Ralston et al, “Characterization of Hepatitis C Virus . . . ”, J. Virol 67:6753-6761, 1993.
Bosman F et al: Purification of the hepatitis C virus envelope proteins and analysis of their oligomeric state. 48th Annual Meeting of the American Association for the Study of Liver Diseases, Chicago, Illinois, USA, Nov. 7-11, 1997. Hepatology 26 (4 Part 2). 1997. 412A, XP002087226 see abstract 1136.
Ristoni et al, Compositional bias and mimicry toward the nonself proteome in immunodominant T cell epitopes of self and nonself antigens. FASEB (2000) vol. 14, No. 3, pp. 431-438.
Paul, Fundamental Immunology, Raven Press, New York, NY 1993, 3rdEdition, p. 251, column 1, lines 11-12.
Baumert et al, Hepatisis C virus structural proteins assemble into virus like particles in insect cells. Journal of Virology (May 1998) vol. 72, No. 5. pp. 3827-3836.
Houghton et al., (1995) Prospects for prophylactic and therapeutic hepatitis C virus vaccines. Princess Takamatsu Symp 25, 237-243.
Houghton et al., (1997) Development of an HCV vaccine. In: Viral Hepatitis and Liver Disease (Rizetto, Purcell, Gerin, Verme, eds), Edizioni Minerva Medica (Turin, Italy), pp. 656-659.
Large et al., (1999) Supression of Host Immune Response by the Core Protein of Hepatitis C Virus: Possible Implications for Hepatitis C Virus Persistence, The American Association of Immunologies, pp. 931-938.
Leroux-Roels et al. 2001 (Hepatology 34, 449A).
Nevens et al. 2003 (Hepatology 38, 1289-1296).
Pawlotsky and McHutchison 2003 (Hepatology 39, 554-567).
Botarelli et al. 1993 (Gastroenterology 104, 580-587).
Major et al. 2002 (J Virol 76, 6586-6595).
Bassett et al. 2001 (Hepatology 33, 1479-1487).
Weiner et al. 2001 (J Virol 75, 7142-7148).
Mehta et al. 2002 (Lancet 359, 1478-1483).
Bosman Fons
Depla Erik
Maertens Geert
Housel James
Innogenetics N.V.
Li Bao Qun
Nixon & Vanderhye P.C.
LandOfFree
Purified hepatitis C virus envelope proteins for diagnostic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Purified hepatitis C virus envelope proteins for diagnostic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Purified hepatitis C virus envelope proteins for diagnostic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3556582